Welcome to our dedicated page for Virios Therapeutics SEC filings (Ticker: VIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Virios Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Virios Therapeutics's regulatory disclosures and financial reporting.
Dogwood Therapeutics, Inc. (VIRI) filed a Form S-8 to register 108,612 additional shares of common stock for issuance under its Amended and Restated 2020 Equity Incentive Plan. The new shares supplement prior S-8 registrations (Dec 21 2020 and Jun 22 2022) and follow Board authorization on Apr 17 2025 and shareholder approval on Jun 18 2025. Standard incorporation-by-reference, exhibits (legal opinion, auditor consent, plan document) and undertakings are included. The filing is an administrative step to ensure sufficient shares are available for employee equity awards and does not provide new financial results or strategic disclosures.